Alice Blue - 20 years of trust
    • ANT APP
    • ANT WEB
    • 1LyAlgos
    • 1lyOptions
    • TradingView
    • MTF
    • Insurance
    • IPO
    • Stocks
    • Mutual Funds
  • Partner with us
  • Trade School
  • Pricing

    • Pricing

    About Us

    • About Us

    Calculator

    • Calculators
    • Brokerage Calculator
    • MTF Calculator

    Resources

    • Blog
    • Webinars
    • Videos (YouTube)

    Updates

    • News
    • Trading Holidays
    • Cares
    • Media Coverage
    • Disclosures

    Support

    • Support
    • Refer & Earn
    CommunityCareers
Login

    Start Investing in Stocks₹0 Account Opening

    +91
    Top Gainers Today52 Weeks High StocksHistorical Returns StocksShare Market TodayTop Losers TodayStocks Market NewsYes BankPC JewellerVodafone IdeaBillionbrainsTata Tele. Mah.MoneyviewM T N LHDFC BankSuzlon EnergyV2 RetailTata Gold ETFIndiabullsSamvardh. Mothe.Motisons JewelNip. India GoldGTL Infra.Tata Silver ETFJSW CementOla Electric
    NIFTY 50NIFTY Midcap 100NIFTY 100NIFTY RealtySENSEXNIFTY AutoNIFTY PSU BankNIFTY FMCGNIFTY BANKNIFTY MIDCAP 150BSE EnergyNIFTY PharmaBSE 100 LargeCap TMCNIFTY NEXT 50NIFTY MetalBSE 500 QUALITY 50
    Options Nifty 50Options BANK NIFTYOptions MIDCPNIFTYOptions FINNIFTYFutures Highest OIFutures OI GainersFutures OI LosersFutures Top Traded
    Debt Mutual FundsBest Debt Mutual fundsBest Equity Mutual fundsBest Hybrid Mutual fundsBest MidCap Mutual fundsBest Multicap Mutual fundsBest Large Cap Mutual fundsBest Small Cap Mutual fundsBest ELSS Mutual fundsBest Contra Mutual fundsBest Value Mutual fundsBest Arbitrage Mutual fundsBest Dividend Yield Mutual fundBest Aggressive Mutual fundsBest Conservative Mutual funds
    SIP CalculatorBrokerage CalculatorHome Loan EMI CalculatorLumpsum CalculatorMargin CalculatorFD CalculatorSWP CalculatorMF CalculatorEMI CalculatorStep-Up SIP CalculatorPPF Calculator
    What Is IPO?Open IPOsUpcoming IPOsHow to Apply for an IPOWhat is Grey Market Premium?
    Shares
    Top Gainers Today52 Weeks High StocksHistorical Returns StocksShare Market TodayTop Losers TodayStocks Market NewsYes BankPC JewellerVodafone IdeaBillionbrainsTata Tele. Mah.MoneyviewM T N LHDFC BankSuzlon EnergyV2 RetailTata Gold ETFIndiabullsSamvardh. Mothe.Motisons JewelNip. India GoldGTL Infra.Tata Silver ETFJSW CementOla Electric
    Indices
    NIFTY 50NIFTY Midcap 100NIFTY 100NIFTY RealtySENSEXNIFTY AutoNIFTY PSU BankNIFTY FMCGNIFTY BANKNIFTY MIDCAP 150BSE EnergyNIFTY PharmaBSE 100 LargeCap TMCNIFTY NEXT 50NIFTY MetalBSE 500 QUALITY 50
    F&O
    Options Nifty 50Options BANK NIFTYOptions MIDCPNIFTYOptions FINNIFTYFutures Highest OIFutures OI GainersFutures OI LosersFutures Top Traded
    Mutual Funds
    Debt Mutual FundsBest Debt Mutual fundsBest Equity Mutual fundsBest Hybrid Mutual fundsBest MidCap Mutual fundsBest Multicap Mutual fundsBest Large Cap Mutual fundsBest Small Cap Mutual fundsBest ELSS Mutual fundsBest Contra Mutual fundsBest Value Mutual fundsBest Arbitrage Mutual fundsBest Dividend Yield Mutual fundBest Aggressive Mutual fundsBest Conservative Mutual funds
    Calculators
    SIP CalculatorBrokerage CalculatorHome Loan EMI CalculatorLumpsum CalculatorMargin CalculatorFD CalculatorSWP CalculatorMF CalculatorEMI CalculatorStep-Up SIP CalculatorPPF Calculator
    IPO
    What Is IPO?Open IPOsUpcoming IPOsHow to Apply for an IPOWhat is Grey Market Premium?

    Company
    • About Us
    • Work with Us
    • Terms and Conditions
    • EKYC Guidelines
    • Contact Us
    • Cares
    Apps and Products
    • ANT APP
    • ANT WEB
    • 1LYOptions
    • Trade School
    • TradingView
    • 1LyAlgos
    Calculators
    • Calculators
    • SIP Calculator
    • Mutual Funds Return Calculator
    • Brokerage Calculator
    • RMS Live Updates
    • Term Coverage Calculator
    Important Links
    • Pricing
    • KYC Tracker
    • Market News
    • Global Indices
    • Gold Rate
    • Silver Rate
    • Trading Holidays

    Alice Blue
    3rd Floor, M.R.B.Arcade, No. 153/2,
    Bagalur Main Rd, Dwarka Nagar,
    Yelahanka, Bengaluru, Karnataka
    560063
    FacebookLinkedInX (Twitter)YouTubeInstagramWhatsapp

    ISO 27001:2022 Alice Blue is Certified Information Security Management System (ISMS)

    ISO 22301:2019 Alice Blue is Certified Business Continuity Management System (BCMS)

    DownloadsCircularsBank DetailsLearn
    Trade on TradingViewGet it on Google PlayDownload on the App Store

    Attention Investors!
    Prevent unauthorized transactions in your account update your mobile number/ email Id with your Stock Broker. Receive information of your transactions directly from Exchange on your mobile / email id at the end of the day.Prevent unauthorized transactions in your account update your mobile number/ email Id with your Stock Broker. Receive information of your transactions directly from Exchange on your mobile / email id at the end of the day.

    Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from the depository on your email id and/or mobile number to create a pledge. Pay 20% upfront margin of the transaction early to trade in the cash market segment. Investors may please refer to the Exchange’s Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020, and NSE/INSP/45534 dated August 31, 2020, and other guidelines issued from time to time in this regard. Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.

    Corporate Office: No. 153/2, 3rd Floor, M.R.B.Arcade, Bagalur Main Road, Dwaraka Nagar, Yelahanka, Bengaluru – 560 063, Karnataka.
    Registered Office: Old No.56/2 ,New No.58, LIC Nagar, Vinayagar Kovil Street, Erode -8,Tamil Nadu– 638002.
    Alice Blue Financial Services (P) Ltd : NSE EQ | NSE FO | NSE CDS-90112 SEBI REG : INZ000156038
    Alice Blue Financial Services (P) Ltd : BSE EQ | BSE FO | BSE CD-6670 SEBI REG : INZ000156038
    Alice Blue Financial Services (P) Ltd : CDSL DP ID 12085300 DP SEBI REG : IN-DP-364-2018
    Alice Blue Financial Services (P) Ltd : MCX-56710 SEBI REG : INZ000156038

    COMPLIANCE OFFICER: SARAVANAN R | Mobile No: +91 91872 10670 | Email:[email protected]

    We hereby declare that we are doing PRO trading

    Procedure to file a complaint on SEBI SCORES / SMART ODR : Register on SEBI SCORES 2.0 / SMART ODR. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances

    Click on the provided link to learn about the process for submitting a complaint on the ODR platform for resolving investor grievances. ODR Circular

    Investment in securities markets are subject to market risks, read all the related documents carefully before investing. Brokerage will not exceed SEBI prescribed limit.

    For queries regarding account opening or activation, email to accountactivation@aliceblueindia.com and for fund updates, email to funds@aliceblueindia.com

    Disclaimer: Attention investors:1) Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors. 2) Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary. 3) Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. 4) For demat and trading account closure with AliceBlue, kindly visit https://aliceblueonline.com/support/closure-freezing-reactivation or “ANT APPLICATION” under your profile and click on Settings -> Account Closure section -> Initiate account closure.

    No need to issue cheques by investors while subscribing to an IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in the investor’s account.

    Investors are requested to note that Alice Blue Financial Services Private Limited is permitted to receive money from investor through designated bank accounts only named as Up streaming Client Nodal Bank Account (USCNBA). Alice Blue Financial Services Private Limited is also required to disclose these USCNB accounts to Stock Exchange. Hence, you are requested to use following USCNB accounts only for the purpose of dealings in your trading account with us. The details of these USCNB accounts are also displayed by Stock Exchanges on their website under “Know/ Locate your Stock Broker. Bank Details (Valid UPI FAQ).

    DND PolicyInvestor CharterLegal DocumentationPrivacy policyFeedbackAnnual ReturnsAdvisory for InvestorsE-votingMandatory Member Details

    Performance

    Historical price movement and trading activity

    Trading Data

    Today's High

    2266.4

    Today's Low

    2143

    Open

    2179

    Previous Close

    2245

    Volume

    535865

    Total Traded Value High

    1190455324.3

    Technicals

    Price-based indicators and levels

    Indicators

    IndicatorValueSignal
    Relative Strength Index (RSI)+80.59Overbought
    MACD+45.69Bullish

    Support and Resistance Levels

    R32416.67
    R22341.53
    R12293.27
    S12169.87
    S22094.73
    S32046.47

    Moving Averages

    PeriodSMAEMA
    20D Moving Average1877.561929.09
    50D Moving Average1906.361903.34
    200D Moving Average1734.181752.76
    Emcure Pharmaceuticals Ltd

    Emcure Pharmaceuticals Ltd

    NSE: EMCURE | BSE: 544210
    ₹2228.1-16.90 (-0.75%)
    BuySell

    News

    Volumes soar at Emcure Pharmaceuticals Ltd counter

    4 Nov 2026

    Emcure Pharmaceuticals Ltd clocked volume of 1.27 lakh shares by 10:48 IST on BSE, a 9.77 times surge over two-week average daily volume of 13045 shares

    SBI Life Insurance Company Ltd, Info Edge (India) Ltd, Can Fin Homes Ltd, HEG Advanced Materials Ltd are among the other stocks to see a surge in volumes on BSE today, 04 November 2026. Emcure Pharmaceuticals Ltd clocked volume of 1.27 lakh shares by 10:48 IST on BSE, a 9.77 times surge over two-week average daily volume of 13045 shares. The stock gained 9.08% to Rs.2,162.50. Volumes stood at 35222 shares in the last session. SBI Life Insurance Company Ltd recorded volume of 7.52 lakh shares by 10:48 IST on BSE, a 8.71 times surge over two-week average daily volume of 86361 shares. The stock gained 0.26% to Rs.1,690.00. Volumes stood at 37017 shares in the last session. Info Edge (India) Ltd witnessed volume of 5.04 lakh shares by 10:48 IST on BSE, a 6.53 times surge over two-week average daily volume of 77274 shares. The stock dropped 0.65% to Rs.1,170.40. Volumes stood at 2.42 lakh shares in the last session. Can Fin Homes Ltd saw volume of 3.02 lakh shares by 10:48 IST on BSE, a 4.67 fold spurt over two-week average daily volume of 64671 shares. The stock dropped 0.41% to Rs.733.20. Volumes stood at 5.06 lakh shares in the last session. HEG Advanced Materials Ltd clocked volume of 4.77 lakh shares by 10:48 IST on BSE, a 4.53 times surge over two-week average daily volume of 1.05 lakh shares. The stock gained 7.79% to Rs.259.50. Volumes stood at 1.3 lakh shares in the last session.

    Emcure Pharmaceuticals faces Rs 57.74 crore in penalty orders from the Income-tax Department

    2 Oct 2026

    Emcure Pharmaceuticals Limited has disclosed receiving penalty orders totaling Rs 57,73,96,732 from the Income-tax Department related to financial years 2014-15 through 2020-21 (assessment years 2015-16 to 2021-22), as revealed in documents submitted to the National Stock Exchange of India Limited and BSE Limited on October 2, 2026. The company is currently evaluating legal options, including filing an appeal before the Appellate Authority, in response to these orders which stem from ongoing litigations previously disclosed in governance reports up to the quarter ended June 30, 2026.

    Emcure Pharmaceuticals secures reaffirmed CARE ratings, alongside Gennova Biopharmaceuticals stake acquisition

    1 Sept 2026

    Emcure Pharmaceuticals Ltd. announced reaffirmations from CARE Ratings Limited and CARE Ratings Ltd. regarding several instruments, including Long-term bank facilities totaling Rs 785.00, Long-term/Short-term bank facilities amounting to Rs 1,563.00, and Short-term bank facilities of Rs 52.00, all carrying ratings of CARE AA; Stable and CARE A1+ respectively, with enhancements to the amounts from Rs 557.50 and Rs 1,348.00 previously; additionally, CARE Ratings Limited (CareEdge Ratings) noted potential for a positive rating upgrade if total operating income and PBILDT margins exceed 22%, while a downgrade could occur if net debt to PBILDT rises above 1.50x or PBILDT margins fall below 15%, alongside the withdrawal of ratings for Non-convertible debentures LT as of January 5, 2024, and the completion of the acquisition of a stake in Gennova Biopharmaceuticals Limited for approximately Rs 232 crore in July 2026, alongside a divestment of its mRNA business for roughly Rs 140 crore.

    Emcure Pharma divests mRNA business for Rs 139.5 crore to Immunoscript Life Science

    11 Jul 2026

    Emcure Pharmaceuticals said that its subsidiary at Gennova Biopharmaceuticals has executed a business transfer agreement for transfer of its mRNA business as a going concern on a slump sale basis to Immunoscript Life Science.

    For FY2025-26, the revenue and the networth of the mRNA business of Gennova Biopharmaceuticals were Rs 64.71 crore (0.71% of consolidated revenue of Emcure Pharma) and Rs 132.63 crore (2.68% of consolidated net worth of Emcure Pharma), respectively. The mRNA business business has been divested for a total cash consideration of Rs 139.5 crore. Emcure Pharma expects the transaction to be completed by 17 July 2026. The company stated that the transfer of mRNA business is part of Gennova's strategic initiative to reorganize its business operations and focus on core areas, which are research and development, manufacturing and marketing of biotechnology-based products including biosimilars and adjacent therapeutic platforms. Pune-based Emcure Pharmaceuticals develops and manufactures a wide range of differentiated pharmaceutical products designed to improve patient health and well-being across several major therapeutic areas. Emcure is present in 70+ countries globally, including Europe and Canada. On a consolidated basis, Emcure Pharmaceuticals' net profit rose 28.81% to Rs 243.40 crore while net sales rose 16.70% to Rs 2469.70 crore in Q4 March 2026 over Q4 March 2025. The scrip rose 0.15% to end at Rs 1810.45 on the BSE on Friday. Powered by Capital Market - Live News

    Emcure Pharma climbs after foreign brokerage reiterates Buy call, lifts target

    23 Jun 2026

    Emcure Pharmaceuticals jumped 5.10% to Rs 1,882.40 after a foreign brokerage reiterated its 'Buy' rating on the stock and raised its target price to Rs 2,100 from Rs 1,970.

    The revised target price implies a potential upside of about 11.6% from the current market price. The brokerage remains optimistic on Emcure's growth prospects and expects the company to deliver low- to mid-teen revenue growth in FY27. It also forecasts EBITDA margin expansion of 75-100 basis points during the year. According to the brokerage, margin improvement is likely to be driven by higher productivity of the company's field force in India and new product launches across key international markets. The brokerage highlighted Emcure's focus on research and development-backed products as a key pillar of its long-term growth strategy. Reflecting its improved outlook, the brokerage raised its earnings per share (EPS) estimates by 1-5% and expects the company to deliver an EPS compound annual growth rate (CAGR) of around 20% over FY26-FY29. Pune-based Emcure Pharmaceuticals develops and manufactures a wide range of differentiated pharmaceutical products designed to improve patient health and well-being across several major therapeutic areas. Emcure is present in 70+ countries globally, including Europe and Canada. On a consolidated basis, Emcure Pharmaceuticals' net profit rose 28.81% to Rs 243.40 crore while net sales rose 16.70% to Rs 2469.70 crore in Q4 March 2026 over Q4 March 2025. Powered by Capital Market - Live News

    Trade now

    Overview

    Pharmaceuticals - Indian - Bulk Drugs & Formln LrgNSE / BSE

    Emcure Pharmaceuticals Limited was originally incorporated as Emcure Pharmaceuticals Private Limited', as a Private Company, pursuant to a Certificate of Incorporation dated April 16, 1981 issued by Registrar of Companies, Maharashtra at Bombay. Subsequently, Company was converted into a Public Company and the name of Company was changed to Emcure Pharmaceuticals Limited', through a fresh Certificate of Incorporation issued by the RoC, Maharashtra in Pune on September 18, 2001. Emcure Pharmaceuticals an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. In India, they are present across acute and chronic therapeutic areas, and their key therapeutic areas include gynecology, cardiovascular, vitamins, minerals and nutrients, human immunodeficiency virus antivirals, blood-related and oncology/anti-neoplastics. The Company has 13 manufacturing facilities across India. It keeps a strong track record in developing portfolios of differentiated products, including chiral molecules, complex APIs, biologics and novel drug delivery systems. It has a portfolio of 11 chiral molecules, of which 6 have been launched so far. In year 1999, Lasor Drugs Limited was amalgamated with the Company. Thereafter, Emcure Laboratories Private Limited., Lasor Laboratories Limited, Lasor Remedies Limited, Nucron Pharmaceuticals Limited and Hiraral Mehta Sales Private Limited were amalgamated with Company during the period 2001. The Company established facility in Kurkumbh in 2006 and then started operations of injectables facility in Hinjawadi. The facility established by Company's Subsidiary, Gennova Biopharmaceuticals Limited at Hinjawadi became operational. The Company started operations in solid orals at facility in Jammu in 2009. During 2012, it acquired rights of BiCNUr, a branded oncology product prescribed for treatment of brain tumors, multiple myeloma, Hodgkin's disease and non-Hodgkin's lymphoma. Through Subsidiary, Zuventus Healthcare Limited, a manufacturing facility was established in Bengaluru in year 2017 and finally, the Company received licence to work a factory at Sanand, Gujarat in 2018. The subsidiary, Tillomed France S.A.S., was incorporated in France in 2018. The Subsidiary, Emcure Pharma Chile SpA, was incorporated in Chile in 2020. The Company has a portfolio of six commercialized and in-house manufactured biologics and biologics brands, Elaxim, Tenectase and Hamsyl, each launched into domestic market for the Financial Year 2021. The Company launched biosimilar for Tenecteplase, commonly used for acute myocardial infraction, and the biosimilar for Pegylated-asparaginase, commonly used for treating patients with leukemia. It hold the global patent for use of Tenectaplase to treat Acute Ischemic Stroke as a second indication in 2021 and Emcure Pharma Philippines Inc., incorporated in Philippines in 2021-22. Tillomed Malta Ltd, was incorporated in Malta in 2022-23. The Company came up with an Initial Public Offer of issuing 19,375,070 Equity Shares aggregating to Rs 1952.02 Crore comprising a Fresh Issue of 7,946,231 Equity Shares aggregating to Rs 800 Crore and an Offer for Sale of 11,428,839 Equity Shares aggregating to Rs 1152.02 Crore on 5th July, 2024. In FY2025, Emcure entered this high-growth sector with the launch of Emcutix Biopharmaceuticals, a wholly owned subsidiary that consolidates its dermatology operations. The Company entered the fast-growing consumer health segment under the 'Arth' brand, targeting lifestyle and wellness categories with science-backed formulations. During the year 2025-26, Emcure Lifesciences Private Limited was incorporated as wholly-owned subsidiary on 17 June 2025. Emcure Wellness Private Limited also incorporated as wholly-owned subsidiary on 03 July 2025. Torrent Urja 37 Private Limited became the Associate Company of the Company, pursuant to acquisition of stake in it dated 02 June 2025. The Company acquired 20.42% of the shareholding of Zuventus Healthcare Ltd, making it wholly-owned subsidiary w.e.f, October 3, 2025. The Company formed partnership with Novo Nordisk to commercialise Poviztra brand (semaglutide injection) has added a new dimension to cardio-metabolics space in 2026. It also partnered with Roche to strengthen the nephrology and transplant care platform, while extending the partnership with Sanofi for oral anti-diabetes like Cetapin and Amaryl.

    Fundamentals

    Financial strength and ownership structure

    Valuation & Ratios

    Market Capitalisation

    ₹30,257.54

    Price to Book (PB)

    6.11

    Price to Earnings (PE)

    32.73

    Return on Equity (ROE)

    20.04%

    Earnings Per Share (EPS)

    49.65

    Dividend Yield

    0.23%

    Financial Performance

    1771.36
    1815.14
    2001.98
    1962.63
    2116.25
    2100.54
    2269.82
    2363.48
    2469.70
    2580.45
    2820.47
    Mar
    '24
    Jun
    '24
    Sep
    '24
    Dec
    '24
    Mar
    '25
    Jun
    '25
    Sep
    '25
    Dec
    '25
    Mar
    '26
    Jun
    '26
    Sep
    '26

    Shareholding Pattern

    77.87%
    77.87%
    77.83%
    77.82%
    Dec
    '25
    Mar
    '26
    Jun
    '26
    Sep
    '26